Analysis & Insights

Is Australia Becoming the Next Big Growth Market for Cannabis?

Compass Cannabis is making a big play for cannabis consumers in Australia, calling it the best international market "outside North America".Although the Australian cannabis industr...

Marijuana Legalisation 2.0 – How Edibles and Extracts will Upend the Market

In October 2019, Canada will experience its second wave of marijuana legalisation In the past we've discussed how poorly implemented the legalisation of recreational cannabis has b...

Cannabis Oceania Pt.2: Insights from Prohibition Partners Conference

With plenty of interest in Oceania, all eyes are on New Zealand's upcoming referendum and how the outcome may shape the cannabis industry within the region. Read this article for m...

Intrinsic Value Assessment of Trulieve

Many companies have aimed at making a name for themselves in the cannabis market, but no company has reached a more dominant state-wide position than Trulieve. As we slowly gain tr...

Cannabis Stocks Climb Amid Biden Presidency

Following the apparent victory of Joe Biden against Donald Trump for the U.S. Presidency, the cannabis stock market skyrocketed. It appears that cannabis investors are bullish on t...

Intrinsic Value Assessment of GW Pharmaceuticals

Should you invest in GW Pharmaceuticals' stock? Find out here in this assessment of GWPH's stock and intrinsic value.Since its inception, GW Pharmaceutical (NYSE:GWPH) has been lea...

Are Canopy Growth Stocks Still a Buy?

Few cannabis companies have risen to the heights that Canopy Growth has. But is the Canadian cannabis giant still all it's hyped up to be? In many ways, Canopy Growth (NYSE:CGC) se...

Are Marijuana Stocks On The Rise Again?

In 2019, the bubble well-and-truly burst for pot stocks, sending many investors running for the hills. Now, it looks like we're seeing the cannabis industry rally back up. As we've...

These Two ASX-Listed Cannabis Biotechs are Working on a COVID-19 Treatment

As the COVID-19 pandemic stretches on, many companies are vying to come up with a treatment - including two ASX-listed cannabis companies. Throughout the world, over 25 million cas...

Is MGC Pharma Sitting on a Potential Treatment for COVID-19?

MGC Pharmaceuticals is scheduled to release results from its interim analysis of the double-blind Phase II clinical trials on its anti-inflammatory formula 'ArtemiC' on patients wi...